Search form
Search
contact us
Navigation
home
boards
Jobs
job ratings
cp wire
medtech news
pharmagather
catering
advertise
whistleblower info
pharmaceutical fraud
medical device | DME fraud
clinical lab fraud
False Claims Act
Legal Help
login/register
You are here
Home
»
companies
» Intercept Pharma
Intercept Pharma
Reeling From FDA Rejection, Intercept Pharma Slashes Headcount by 25%
Xconomy
Tue, 09/1/20 - 10:45 pm
Intercept Pharma
layoffs
NASH
FDA
Ocaliva
Intercept CEO lays into FDA after NASH drug rejection
Pharmaforum
Tue, 06/30/20 - 10:32 am
Intercept Pharma
Pharma CEOs
NASH
FDA
obeticholic acid
Intercept hits regulatory snag at FDA, likely delaying NASH drug’s approval
MedCity News
Fri, 05/22/20 - 10:43 am
Intercept Pharma
obeticholic acid
FDA
NASH
FDA moots virtual AdComms but delays GSK, Intercept meetings
Fierce Biotech
Fri, 03/27/20 - 10:28 am
FDA
advisory panels
GSK
Intercept Pharma
Where Will Intercept Pharmaceuticals Be in 5 Years?
Motley Fool
Fri, 01/24/20 - 11:06 am
Intercept Pharma
Ocaliva
While expected, Intercept's approval delay adds to NASH uncertainty
BioPharma Dive
Sat, 01/18/20 - 07:33 pm
Intercept Pharma
NASH
FDA
obeticholic acid
Will we see the world's first approved NASH drug in 2020?
Fierce Biotech
Fri, 12/20/19 - 10:20 am
NASH
Intercept Pharma
Genfit
As NASH shifts again, the focus remains on Genfit’s big readout
EP Vantage
Wed, 12/18/19 - 10:53 am
NASH
Genfit
elafibranor
Pfizer
Boehringer Ingelheim
Gilead Sciences
Poxel
Takeda
Intercept Pharma
Poxel taking two shots at NASH as pharma waits on FDA’s Ocaliva verdict
Pharmaforum
Wed, 11/20/19 - 10:17 pm
Intercept Pharma
Poxel
NASH
Ocaliva
PXL065
PXL770
Intercept aims to triple sales force as it gears up for potential NASH launch
Fierce Pharma
Thu, 11/14/19 - 07:42 pm
Intercept Pharma
hirings
drug reps
NASH
drug launches
Ocaliva
obeticholic acid
NASH drugmaker stocks rebound after dip on FDA guidance
Biopharma Dive
Mon, 06/10/19 - 06:08 pm
NASH
FDA
Madrigal Pharmaceuticals
Viking Therapeutics
Intercept Pharma
Genfit
Intercept stock drop reflects the high bar set for NASH drugs
BioPharma Dive
Sat, 02/23/19 - 04:52 pm
Intercept Pharma
Ocaliva
NASH
clinical trials
While we wait for NASH data, Genfit reports positive elafibranor data in PBC patients
Endpoints
Thu, 12/6/18 - 10:02 am
Genfit
NASH
Gilead Sciences
Intercept Pharma
clinical trials
elafibranor
NASH drugs come into focus as field awaits late-stage data
BioSpace
Sat, 11/10/18 - 12:43 pm
NASH
Intercept Pharma
Gilead Sciences
Genfit
Allergan
Intercept superstar: revenues exceeding estimates, solid plans and shares rise 10%
GoinPharma
Sun, 08/5/18 - 12:35 pm
Intercept Pharma
earnings
3 Biotech Stocks With Big News Coming in NASH
Motley Fool
Sat, 07/14/18 - 01:11 pm
NASH
Viking Therapeutics
Gilead Sciences
Intercept Pharma
VK2809
Ocalivia
selonsertib
Pharma turn to NASH unlikely to mirror meteoric rise of hep C
Biopharma Dive
Mon, 05/21/18 - 06:25 pm
NASH
Intercept Pharma
obeticholic acid
Top drugmakers are counting on two hot drug fields—migraine and NASH—but payers are ready to rumble
Fierce Pharma
Thu, 02/22/18 - 11:28 pm
migraines
NASH
Amgen
Eli Lilly
Teva Pharmaceutical
Allergan
Gilead Sciences
Novo Nordisk
Intercept Pharma
PBMs
FDA adds black box warning to Intercept's Ocaliva
Biopharma Dive
Thu, 02/1/18 - 09:32 pm
FDA
black box
Intercept Pharma
Ocaliva
liver disease
After 19 Die, Intercept CEO Insists Drugmaker Is Still on Track
Bloomberg
Fri, 09/29/17 - 09:46 am
Intercept Pharma
NASH
clinical trials
Ocaliva
Pages
« first
‹ previous
1
2
3
4
5
next ›
last »